# Low PSMA SUV Boost (LPS-Boost): Intensified 177Lu-PSMA-617 Treatment for Patients With Metastatic Castrate-Resistant Prostate Cancer With Low PSMA Expressing Disease

> **NCT06526299** · PHASE2 · RECRUITING · sponsor: **University of Washington** · enrollment: 51 (estimated)

## Conditions studied

- Metastatic Castration-Resistant Prostate Carcinoma
- Stage IVB Prostate Cancer AJCC v8

## Interventions

- **PROCEDURE:** Biospecimen Collection
- **PROCEDURE:** Bone Scan
- **PROCEDURE:** Computed Tomography
- **DRUG:** Lutetium Lu 177 Vipivotide Tetraxetan
- **PROCEDURE:** Magnetic Resonance Imaging
- **PROCEDURE:** PSMA PET-CT Scan
- **OTHER:** Questionnaire Administration
- **PROCEDURE:** Single Photon Emission Computed Tomography

## Key facts

- **NCT ID:** NCT06526299
- **Lead sponsor:** University of Washington
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2025-04-29
- **Primary completion:** 2027-12-31
- **Final completion:** 2027-12-31
- **Target enrollment:** 51 (ESTIMATED)
- **Last updated:** 2026-03-24

## Collaborators

- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06526299

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06526299, "Low PSMA SUV Boost (LPS-Boost): Intensified 177Lu-PSMA-617 Treatment for Patients With Metastatic Castrate-Resistant Prostate Cancer With Low PSMA Expressing Disease". Retrieved via AI Analytics 2026-07-24 from https://api.ai-analytics.org/clinical/NCT06526299. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*